Ian Ingram is the Deputy Managing Editor for MedPage Today, a leading source of medical news and information for healthcare professionals. With a focus on medical research and advancements, Ian covers a wide range of topics including oncology, hematology, and drug approvals.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Ian Ingram's coverage is primarily focused on healthcare and pharmaceuticals, with a particular emphasis on clinical trial results, FDA approvals, and drug treatments for cancer and leukemia. He frequently cites data in his articles, indicating an interest in evidence-based reporting.
Pitching to Ian should involve providing access to newly released or exclusive clinical trial data, insights from key opinion leaders in the field of oncology or pharmaceuticals regarding recent developments in cancer treatment or FDA approval processes.
It's important to note that Ian does not have a specific geographic focus but covers international healthcare and pharmaceutical topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ian Ingram
— Better disease outcomes, measures of cognition, and quality-of-life vs standard care, study finds
By: Ian Ingram
— But no overall survival benefit seen in confirmatory trial SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other
— DREAMM-7 findings help pave the way for Blenrep's return SAN DIEGO -- A significant overall survival (OS) benefit with belantamab
— Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis
— Mostly expired drugs are no longer effective against circulating SARS-CoV-2 strains
— Nemolizumab indicated for chronic skin disease in adults and kids ages 12 years and up
FDA approves tapinarof cream 1% for adults and kids 2 years and up
Hall of Fame football player recently revealed his cholangiocarcinoma diagnosis
By: Ian Ingram
— Off-the-shelf product indicated for cases where autologous vein harvesting is not an option
— CFTR modulator carries boxed warning over risk of drug-induced liver injury and liver failure
(833) 317-6278 
